Status:
RECRUITING
Single Cell Sequencing and Multidimensional Omics Studies in Cardiovascular and Neurological Diseases
Lead Sponsor:
Tao Xin
Conditions:
Nervous System Diseases
Cardiovascular Diseases
Eligibility:
All Genders
18-75 years
Brief Summary
Research purpose Using single-cell sequencing, 3D/4D genomics and multidimensional omics technologies to reveal the complex cellular and molecular regulatory networks of cardiovascular and nervous sys...
Detailed Description
1. Test population Disease-specific experimental cohort of cardiovascular and neurological diseases (atrial fibrillation secondary to valvular heart disease, carotid atherosclerosis, moyamoya disease)...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Inclusion criteria for patients with valvular atrial fibrillation:
- Moderate or above mitral valve disease; The occurrence of atrial fibrillation was recorded by 12-lead electrocardiogram or 24-hour holter electrocardiogram. 3.18≤ Age ≤75 years old.
- Inclusion criteria for disease control of valvular atrial fibrillation:
- No moderate or above mitral valve disease; No history of atrial fibrillation, 24-hour holter electrocardiogram did not record the occurrence of atrial fibrillation. 3.18≤ Age ≤75 years old.
- Inclusion criteria for carotid atherosclerosis cases:
- Carotid atherosclerosis was confirmed by ultrasound, CTA and other imaging diagnosis. 2.18≤ Age ≤75 years old.
- Inclusion criteria for carotid atherosclerosis control:
- The inclusion criteria for carotid atherosclerosis cases were met. The peripheral tissue of the vascular plaque was discarded in the same patient.
- Inclusion criteria for moyamoya disease cases:
- Imaging diagnosis confirmed moyamoya disease; 2.18≤ Age ≤75 years old.
- Moyamoya disease control inclusion criteria:
- Imaging diagnosis confirmed no moyamoya disease; 2.18≤ Age ≤75 years old.
- Exclusion criteria
- Exclusion criteria for patients with valvular atrial fibrillation:
- Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure and other non-valvular factors cause atrial fibrillation.
- Exclusion criteria for control of valvular atrial fibrillation:
- Coronary heart disease, myocardial infarction, hyperthyroidism, severe hepatic and renal insufficiency, benign and malignant tumors, etc. Dilated cardiomyopathy, hypertrophic cardiomyopathy, congenital heart disease, heart failure, etc.
- Exclusion criteria for carotid atherosclerosis cases:
- History of carotid vascular surgery or trauma
- Exclusion criteria for carotid atherosclerosis control:
- No plaque margin tissue or marginal tissue injury was found in abandoned vessels in the same patient.
- Exclusion criteria for moyamoya disease cases:
- Previous history of cerebrovascular surgery or trauma.
- Exclusion criteria for moyamoya disease control:
- Previous history of cerebrovascular surgery or trauma.
Exclusion
Key Trial Info
Start Date :
April 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT06114095
Start Date
April 1 2023
End Date
April 30 2026
Last Update
November 2 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital
Jinan, Shandong, China, 250000